As the 2024 U.S. presidential election nears, the choice between Democratic nominee Vice President Kamala Harris and Republican nominee former President Donald Trump will shape the future of drug pricing policy.  

While both candidates have pledged to reduce drug costs, their approaches are likely to differ significantly.  

In this week's episode of "The Top Line," Fierce Pharma's Zoey Becker chats with John Barkett, managing director of BRG’s healthcare transactions and strategy practice and former senior policy advisor for healthcare delivery system reform on the White House Domestic Policy Council, about what we can expect from each candidate's potential presidency and how the Inflation Reduction Act could play a pivotal role.  

To learn more about the topics in this episode: 

• With election nearing, BMO analysts don't expect major pharma shake-ups from either candidate
• Biden touts drug pricing achievements as he steps down from reelection campaign
• 2024 forecast: Biden admin efforts show there's no pricing relief on the horizon for pharma

See omnystudio.com/listener for privacy information.